Received May 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 3 | — | — |
No additional AE; stated patient is scheduled to receive third dose on 5/16/2025; patient received the 2 dose of GARDASIL 9 doses outside of the schedule regimen within the Prescribing Information on 17-JAN-2025; This spontaneous report was received from a pharmacist on 16-MAY-2025 and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 20-MAR-2024, the patient was vaccinated with a first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), (lot #, expiration date, dose, anatomical location and route of administration were not mentioned) for prophylaxis. On 17-JAN-2025, the patient received the second dose of with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) outside of schedule regimen within the Prescribing Information (lot #, expiration date, dose, anatomical location and route of administration were not mentioned) for prophylaxis (Inappropriate schedule of product administration). Reporter stated patient was scheduled to receive third dose on 16-MAY-2025 (Inappropriate schedule of product administration). No additional adverse event reported. Lot # is being requested and will be submitted if received.